GW Pharma (GWPH) Posts Smaller Q3 Loss

GW Pharma (NASDAQ: GWPH) reported Q3 EPS of ($1.26), $1.41 better than the analyst estimate of ($2.67). Revenue for the quarter came in at $3.46 million versus the consensus estimate of $2.94 million.

Cash and cash equivalents at 30 June 2018 of £334.0 million ($440.2 million) compared to £241.2 million as at 30 September 2017

For earnings history and earnings-related data on GW Pharma (GWPH) click here.

You May Also Be Interested In

• Rivian reports record Q3 deliveries, beats estimates, shares rise
• Integra LifeSciences stock tumbles after cutting 2026 outlook
• Integra LifeSciences cuts 2026 outlook after Cincinnati flood